Sign inJoin waitlistJoin the waitlist

Alberto Montero

Director, Breast Cancer Program, UH Seidman Cancer Center · Case Western Reserve University/University Hospitals Cleveland Medical Center

Credentials: · · · · · ·

History

Breast Cancer Program · Case Western Reserve University/University Hospitals Cleveland Medical Center
Present
University Hospitals Seidman Cancer Center Clinical Trials Unit · Case Western Reserve University
Present
Case Western Reserve University/University Hospitals Cleveland Medical Center
Present

University of Miami
2010–2013
Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2002–2005
Internal Medicine
University of Texas Health Science Center at Houston
1999–2002
University of Miami School of Business
University of Texas Medical Branch at Galveston School of Medicine
1995–1999
University Of Miami
1991–1995

Research

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
Cancer immunology · 2009 · Last of 6 authors · Corresponding · 1,022 citations
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced…
Journal of Clinical Oncology · 2022 · 629 citations
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells
Blood · 2011 · 276 citations

SG
Stefan Gluck
14 papers
Amanda Amin
11 papers
Jame Abraham
11 papers
Avirup Guha
9 papers
SZ
Simon Zeichner
9 papers · 9 as a fellow
Caio Lima
7 papers
Christopher Towe
7 papers
Gilberto Lopes
6 papers
Halle Moore
6 papers
Robert Shenk
6 papers
CV
Charles Vogel
5 papers
David Cole
5 papers

Grants

Enhancing T-Cell Responses with the Glutathione Mimetic NOV-002 in Breast Cancer
National Cancer Institute · K23
Contact PI · $798K · Cleveland Clinic Lerner Com-Cwru
2010–2016

Clinical trials

Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
Principal investigator · Terminated · Phase 2
AEterna Zentaris
2012–2014
NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer
Principal investigator · Completed · Phase 2
University of Miami
2007–2011
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Site PI · Recruiting
Carevive Systems, Inc.
2023–2026